web logo
  • Therapies
    • DNX-2401
    • Combination Therapies
  • Diseases
    • Adult Brain Cancer
    • Pediatric Brain Cancer
  • Clinical Trials
    • Pediatric Clinical Trials
    • Adult Clinical Trials
    • Compassionate Use
  • Company
    • Management Team
    • Board of Directors
    • Key Advisors
    • Clinical Partners
  • Investor Resources
    • Company News & Presentations
    • Scientific Publications
    • Investor Presentations
  • Contact

News

CPRIT Provides $10.8M Grant to Advance Breakthrough Oncolytic Virus Therapy for Glioblastoma

Overview The Cancer Prevention & Research Institute of Texas (CPRIT) provided $10.8 million grant to…

Read more

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors…

Read more

Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination

Oncolytic viruses selectively lyse tumor cells, disrupt immunosuppression within the tumor, and reactivate antitumor immunity,…

Read more

Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas

Intratumoral injection of oncolytic adenovirus Delta-24-RGDOX induces efficacious antiglioma immunity in syngeneic glioma mouse models.…

Read more

Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway

Background: Oncolytic adenoviruses are promising therapies for the treatment of gliomas. However, untargeted viral replication…

Read more

Examination of the Therapeutic Potential of Delta-24-RGD in Brain Tumor Stem Cells: Role of Autophagic Cell Death

The eradication of brain tumor stem cells is essential for long-term brain tumor remission after…

Read more

Human Bone Marrow–Derived Mesenchymal Stem Cells for Intravascular Delivery of Oncolytic Adenovirus Δ24-RGD to Human Gliomas

Δ24-RGD is an infectivity-augmented, conditionally replicative oncolytic adenovirus with significant antiglioma effects. Although intratumoral delivery…

Read more

Delta-24-RGD Oncolytic Adenovirus Elicits Anti-Glioma Immunity in an Immunocompetent Mouse Model

Emerging evidence suggests anti-cancer immunity is involved in the therapeutic effect induced by oncolytic viruses.…

Read more

Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma

Delta-24-RGD (DNX-2401) is a conditional replication-competent oncolytic virus engineered to preferentially replicate in and lyse…

Read more
  • 1
  • 2
  • 3
  • >
footer-logo
  • Address

    3400 Edloe Street, Suite 335 Houston, TX 77027

Therapies
  • DNX-2401 (tasadenoturev)
  • Combination Therapies
Diseases
  • Adult Brain Cancer
  • Pediatric Brain Cancer
Science
  • Pediatric Clinical Trials
  • Adult Clinical Trials
Company
  • Management Team
  • Board of Directors
  • Clinical Partners
Contact
  • Terms of Use Policy
  • Privacy Policy

Copyright © 2026. CVBio. All Rights Reserved